AVI BioPharma (AVII) to Present Data for Duchenne Muscular Dystrophy Therapy at TREAT-NMD/NIH Conference

November 19, 2009 8:39 AM EST

AVI BioPharma, Inc. (NASDAQ: AVII) today announced presentations on the company's exon skipping therapy for Duchenne muscular dystrophy at the TREAT-NMD / NIH International Conference taking place Nov. 17-19 in Brussels, Belgium.

At the conference, data from the company's clinical and preclinical programs were presented. An update on the company's ongoing systemic Phase 1b/2 trial of AVI-4658 was provided by Professor Francesco Muntoni, of the MDEX consortium in the UK, during an oral presentation and also summarized in a poster presentation. The most recent data from the ongoing Phase 1b/2 trial at two MDEX sites in the UK demonstrate that AVI-4658 was well tolerated by DMD patients in a dose escalation study that is now up to the sixth and final cohort (20 mg/kg). The maximum cumulative dose administered to date is 3132 mg and the maximum single dose is 900 mg with no adverse safety signals, in either case.

A series of posters were also presented by Peter Sazani, Ph.D., Executive Director of Preclinical Development. Data presented included preclinical findings demonstrating that treatment with AVI-4658 was tolerated at dosages up to 960 mg/kg in mice and up to 320/mg/kg in primates -- both maximum feasible doses.

The aim of the TREAT-NMD Conference is to share progress in the area of translational medicine in inherited neuromuscular diseases and to set the future collaborative agenda.

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?